Rheumatology Therapeutics Market by Disease Type, Drug Type, Distribution Channel and Region – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2030
2.7%
CAGR (2024-2030)
49.04 USD Bn.
Market Size
328
Report Pages
153
Market Tables
Overview
Rheumatology Therapeutics Market size is expected to reach nearly USD 59.10 Bn. by 2030 with the CAGR of 2.7% during the forecast period.
Rheumatology is the discipline of internal medicine that involves the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are characterized by the inflammation that affects joints, tendons, ligaments, bones and sometimes organs.
Global Rheumatology Therapeutics Market is mainly driven by factors such as an Increasing prevalence of rheumatic disorders, increasing geriatric population in developed countries, increase in the number of new drugs approval and growing R&D investments. Also according to world arthritis day, more than 120 million people in the European Union are affected by some of the forms of arthritis. The growing geriatric population in developed countries is likely to be key driving factor for global rheumatology therapeutics market.
To know about the Research Methodology :- Request Free Sample Report
However, introduction of biosimilars is major restraint for rheumatology therapeutics market. Increasing demand for biosimilar may hinder the conventional drug commonly used for rheumatology diseases treatment.
Global Rheumatology Therapeutics Market is segmented by drug class, by disease indication, by route of administration, by distribution channel and by region.
By drug type, the market is segmented into disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs and others. DMARDs drug type segment is expected to exhibit highest market share at a CAGR of xx% over forecast period thanks to an increase in usage of these drugs in early stage of disease and growing adoption of biologics drugs for treatment of moderate to severe rheumatoid arthritis and osteoarthritis.
By geography, Global Rheumatology Therapeutics Market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America dominated the market in 2023 and it is anticipated that North America will keep its dominance over forecast period thanks to increasing geriatric population in this region.
Key players operating in this market are Abbvie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., and Takeda Pharmaceutical. Among them, the companies such as AbbVie, Inc. These players are adopting various organic and inorganic growth strategies such as merger & acquisition, Joint ventures, expansion, strategic alliances, new product launches etc. to enhance their regional presence and business operation.
The objective of the report is to present a comprehensive analysis of Global Rheumatology Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Rheumatology Therapeutics Market dynamics, structure by analysing the market segments and project the Global Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product Portfolio, Growth strategies, and Regional presence in the Global Rheumatology Therapeutics Market make the report investor’s guide.
The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.
Rheumatology Therapeutics Market Scope: Inquire before buying
| Global Rheumatology Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | USD 49.04 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 2.7% | Market Size in 2030: | USD 59.10 Bn. |
| Segments Covered: | by Disease Type | Rheumatoid Arthritis Ankylosing Spondylitis Osteoarthritis Lupus Gout Others |
|
| by Drug Type | Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Analgesics Disease Modifying Anti-Rheumatic Drugs (DMARDs) Corticosteroids Uric Acid Others |
||
| by Distribution Channel | Retail Pharmacy Online Pharmacy Hospitals Others |
||
Rheumatology Therapeutics Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Rheumatology Therapeutics Market Key Players
1. Abbvie, Inc.
2. Bristol-Myers Squibb Company,
3. Pfizer, Inc.
4. Merck & Co., Inc.
5. Amgen, Inc.
6. Novartis AG
7. Janssen Biotech, Inc.
8. Sanofi
9. Genentech, Inc.
10.Takeda Pharmaceutical
11.Johnson & Johnson Private Limited
12.F. Hoffmann-La Roche Ltd
13.UCB S.A.
14.Gilead Sciences, Inc.
15.Boehringer Ingelheim International GmbH
16.Regeneron Pharmaceuticals Inc.
Frequently Asked Questions:
1. Which region has the largest share in Global Rheumatology Therapeutics Market?
Ans: North America region held the highest share in 2023.
2. What is the growth rate of Global Rheumatology Therapeutics Market?
Ans: The Global Rheumatology Therapeutics Market is growing at a CAGR of 2.7% during forecasting period 2024-2030.
3. What is scope of the Global Rheumatology Therapeutics market report?
Ans: Global Rheumatology Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Rheumatology Therapeutics market?
Ans: The important key players in the Global Rheumatology Therapeutics Market are – Abbvie, Inc., Bristol-Myers Squibb Company,, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., Takeda Pharmaceutical, Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd, UCB S.A., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, and Regeneron Pharmaceuticals Inc.
5. What is the study period of this market?
Ans: The Global Rheumatology Therapeutics Market is studied from 2023 to 2030.
Table of Contents
Global Rheumatology Therapeutics Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.2. Secondary data
2.3.3. Secondary Sources
2.3.4. Primary Research
2.3.5. Data from Primary Sources
2.3.6. Breakdown of Primary Sources
3. Executive Summary: Global Rheumatology Therapeutics Market, by Market Value (US$ Mn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Rheumatology Therapeutics Market Analysis and Forecast
6.1. Global Rheumatology Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Rheumatology Therapeutics Market Analysis and Forecast, By Disease Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Rheumatology Therapeutics Market Value Share Analysis, By Disease Type
7.4. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, By Disease Type
7.5. Global Rheumatology Therapeutics Market Analysis, By Disease Type
7.6. Global Rheumatology Therapeutics Market Attractiveness Analysis, By Disease Type
8. Global Rheumatology Therapeutics Market Analysis and Forecast, By Drug Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Rheumatology Therapeutics Market Value Share Analysis, By Drug Type
8.4. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, By Drug Type
8.5. Global Rheumatology Therapeutics Market Analysis, By Drug Type
8.6. Global Rheumatology Therapeutics Market Attractiveness Analysis, By Drug Type
9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel
9.4. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel
9.5. Global Rheumatology Therapeutics Market Analysis, by Distribution Channel
9.6. Global Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel
10. Global Rheumatology Therapeutics Market Analysis, by Region
10.1. Global Rheumatology Therapeutics Market Value Share Analysis, by Region
10.2. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region
10.3. Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region
11. North America Rheumatology Therapeutics Market Analysis
11.1. Key Findings
11.2. North America Rheumatology Therapeutics Market Overview
11.3. North America Rheumatology Therapeutics Market Value Share Analysis, By Disease Type
11.4. North America Rheumatology Therapeutics Market Forecast, By Disease Type
11.4.1. Rheumatoid Arthritis
11.4.2. Ankylosing Spondylitis
11.4.3. Osteoarthritis
11.4.4. Lupus
11.4.5. Gout
11.4.6. Others
11.5. North America Rheumatology Therapeutics Market Value Share Analysis, By Drug Type
11.6. North America Rheumatology Therapeutics Market Forecast, By Drug Type
11.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.6.2. Analgesics
11.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.6.4. Corticosteroids
11.6.5. Uric Acid
11.6.6. Others
11.7. North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel
11.8. North America Rheumatology Therapeutics Market Forecast, by Distribution Channel
11.8.1. Retail Pharmacy
11.8.2. Online Pharmacy
11.8.3. Hospitals
11.8.4. Others
11.9. North America Rheumatology Therapeutics Market Value Share Analysis, by Country
11.10. North America Rheumatology Therapeutics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Rheumatology Therapeutics Market Analysis, by Country
11.12. U.S. Rheumatology Therapeutics Market Forecast, By Disease Type
11.12.1. Rheumatoid Arthritis
11.12.2. Ankylosing Spondylitis
11.12.3. Osteoarthritis
11.12.4. Lupus
11.12.5. Gout
11.12.6. Others
11.13. U.S. Rheumatology Therapeutics Market Forecast, By Drug Type
11.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.13.2. Analgesics
11.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.13.4. Corticosteroids
11.13.5. Uric Acid
11.13.6. Others
11.14. U.S. Rheumatology Therapeutics Market Forecast, by Distribution Channel
11.14.1. Retail Pharmacy
11.14.2. Online Pharmacy
11.14.3. Hospitals
11.14.4. Others
11.15. Canada Rheumatology Therapeutics Market Forecast, By Disease Type
11.15.1. Rheumatoid Arthritis
11.15.2. Ankylosing Spondylitis
11.15.3. Osteoarthritis
11.15.4. Lupus
11.15.5. Gout
11.15.6. Others
11.16. Canada Rheumatology Therapeutics Market Forecast, By Drug Type
11.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
11.16.2. Analgesics
11.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
11.16.4. Corticosteroids
11.16.5. Uric Acid
11.16.6. Others
11.17. Canada Rheumatology Therapeutics Market Forecast, by Distribution Channel
11.17.1. Retail Pharmacy
11.17.2. Online Pharmacy
11.17.3. Hospitals
11.17.4. Others
11.18. North America Rheumatology Therapeutics Market Attractiveness Analysis
11.18.1. By Disease Type
11.18.2. By Drug Type
11.18.3. By Distribution Channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Development
12. Europe Rheumatology Therapeutics Market Analysis
12.1. Key Findings
12.2. Europe Rheumatology Therapeutics Market Overview
12.3. Europe Rheumatology Therapeutics Market Value Share Analysis, By Disease Type
12.4. Europe Rheumatology Therapeutics Market Forecast, By Disease Type
12.4.1. Rheumatoid Arthritis
12.4.2. Ankylosing Spondylitis
12.4.3. Osteoarthritis
12.4.4. Lupus
12.4.5. Gout
12.4.6. Others
12.5. Europe Rheumatology Therapeutics Market Value Share Analysis, By Drug Type
12.6. Europe Rheumatology Therapeutics Market Forecast, By Drug Type
12.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.6.2. Analgesics
12.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.6.4. Corticosteroids
12.6.5. Uric Acid
12.6.6. Others
12.7. Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel
12.8. Europe Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.8.1. Retail Pharmacy
12.8.2. Online Pharmacy
12.8.3. Hospitals
12.8.4. Others
12.9. Europe Rheumatology Therapeutics Market Value Share Analysis, by Country
12.10. Europe Rheumatology Therapeutics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Rheumatology Therapeutics Market Analysis, by Country
12.12. Germany Rheumatology Therapeutics Market Forecast, By Disease Type
12.12.1. Rheumatoid Arthritis
12.12.2. Ankylosing Spondylitis
12.12.3. Osteoarthritis
12.12.4. Lupus
12.12.5. Gout
12.12.6. Others
12.13. Germany Rheumatology Therapeutics Market Forecast, By Drug Type
12.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.13.2. Analgesics
12.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.13.4. Corticosteroids
12.13.5. Uric Acid
12.13.6. Others
12.14. Germany Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.14.1. Retail Pharmacy
12.14.2. Online Pharmacy
12.14.3. Hospitals
12.14.4. Others
12.15. U.K. Rheumatology Therapeutics Market Forecast, By Disease Type
12.15.1. Rheumatoid Arthritis
12.15.2. Ankylosing Spondylitis
12.15.3. Osteoarthritis
12.15.4. Lupus
12.15.5. Gout
12.15.6. Others
12.16. U.K. Rheumatology Therapeutics Market Forecast, By Drug Type
12.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.16.2. Analgesics
12.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.16.4. Corticosteroids
12.16.5. Uric Acid
12.16.6. Others
12.17. U.K. Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.17.1. Retail Pharmacy
12.17.2. Online Pharmacy
12.17.3. Hospitals
12.17.4. Others
12.18. France Rheumatology Therapeutics Market Forecast, By Disease Type
12.18.1. Rheumatoid Arthritis
12.18.2. Ankylosing Spondylitis
12.18.3. Osteoarthritis
12.18.4. Lupus
12.18.5. Gout
12.18.6. Others
12.19. France Rheumatology Therapeutics Market Forecast, By Drug Type
12.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.19.2. Analgesics
12.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.19.4. Corticosteroids
12.19.5. Uric Acid
12.19.6. Others
12.20. France Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.20.1. Retail Pharmacy
12.20.2. Online Pharmacy
12.20.3. Hospitals
12.20.4. Others
12.21. Italy Rheumatology Therapeutics Market Forecast, By Disease Type
12.21.1. Rheumatoid Arthritis
12.21.2. Ankylosing Spondylitis
12.21.3. Osteoarthritis
12.21.4. Lupus
12.21.5. Gout
12.21.6. Others
12.22. Italy Rheumatology Therapeutics Market Forecast, By Drug Type
12.22.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.22.2. Analgesics
12.22.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.22.4. Corticosteroids
12.22.5. Uric Acid
12.22.6. Others
12.23. Italy Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.23.1. Retail Pharmacy
12.23.2. Online Pharmacy
12.23.3. Hospitals
12.23.4. Others
12.24. Spain Rheumatology Therapeutics Market Forecast, By Disease Type
12.24.1. Rheumatoid Arthritis
12.24.2. Ankylosing Spondylitis
12.24.3. Osteoarthritis
12.24.4. Lupus
12.24.5. Gout
12.24.6. Others
12.25. Spain Rheumatology Therapeutics Market Forecast, By Drug Type
12.25.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.25.2. Analgesics
12.25.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.25.4. Corticosteroids
12.25.5. Uric Acid
12.25.6. Others
12.26. Spain Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.26.1. Retail Pharmacy
12.26.2. Online Pharmacy
12.26.3. Hospitals
12.26.4. Others
12.27. Rest of Europe Rheumatology Therapeutics Market Forecast, By Disease Type
12.27.1. Rheumatoid Arthritis
12.27.2. Ankylosing Spondylitis
12.27.3. Osteoarthritis
12.27.4. Lupus
12.27.5. Gout
12.27.6. Others
12.28. Rest of Europe Rheumatology Therapeutics Market Forecast, By Drug Type
12.28.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
12.28.2. Analgesics
12.28.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
12.28.4. Corticosteroids
12.28.5. Uric Acid
12.28.6. Others
12.29. Rest of Europe Rheumatology Therapeutics Market Forecast, by Distribution Channel
12.29.1. Retail Pharmacy
12.29.2. Online Pharmacy
12.29.3. Hospitals
12.29.4. Others
12.30. Europe Rheumatology Therapeutics Market Attractiveness Analysis
12.30.1. By Disease Type
12.30.2. By Drug Type
12.30.3. By Distribution Channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Development
13. Asia Pacific Rheumatology Therapeutics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Rheumatology Therapeutics Market Overview
13.3. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, By Disease Type
13.4. Asia Pacific Rheumatology Therapeutics Market Forecast, By Disease Type
13.4.1. Rheumatoid Arthritis
13.4.2. Ankylosing Spondylitis
13.4.3. Osteoarthritis
13.4.4. Lupus
13.4.5. Gout
13.4.6. Others
13.5. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, By Drug Type
13.6. Asia Pacific Rheumatology Therapeutics Market Forecast, By Drug Type
13.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
13.6.2. Analgesics
13.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.6.4. Corticosteroids
13.6.5. Uric Acid
13.6.6. Others
13.7. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel
13.8. Asia Pacific Rheumatology Therapeutics Market Forecast, by Distribution Channel
13.8.1. Retail Pharmacy
13.8.2. Online Pharmacy
13.8.3. Hospitals
13.8.4. Others
13.9. Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country
13.10. Asia Pacific Rheumatology Therapeutics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Rheumatology Therapeutics Market Analysis, by Country
13.12. China Rheumatology Therapeutics Market Forecast, By Disease Type
13.12.1. Rheumatoid Arthritis
13.12.2. Ankylosing Spondylitis
13.12.3. Osteoarthritis
13.12.4. Lupus
13.12.5. Gout
13.12.6. Others
13.13. China Rheumatology Therapeutics Market Forecast, By Drug Type
13.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
13.13.2. Analgesics
13.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.13.4. Corticosteroids
13.13.5. Uric Acid
13.13.6. Others
13.14. China Rheumatology Therapeutics Market Forecast, by Distribution Channel
13.14.1. Retail Pharmacy
13.14.2. Online Pharmacy
13.14.3. Hospitals
13.14.4. Others
13.15. India Rheumatology Therapeutics Market Forecast, By Disease Type
13.15.1. Rheumatoid Arthritis
13.15.2. Ankylosing Spondylitis
13.15.3. Osteoarthritis
13.15.4. Lupus
13.15.5. Gout
13.15.6. Others
13.16. India Rheumatology Therapeutics Market Forecast, By Drug Type
13.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
13.16.2. Analgesics
13.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.16.4. Corticosteroids
13.16.5. Uric Acid
13.16.6. Others
13.17. India Rheumatology Therapeutics Market Forecast, by Distribution Channel
13.17.1. Retail Pharmacy
13.17.2. Online Pharmacy
13.17.3. Hospitals
13.17.4. Others
13.18. Japan Rheumatology Therapeutics Market Forecast, By Disease Type
13.18.1. Rheumatoid Arthritis
13.18.2. Ankylosing Spondylitis
13.18.3. Osteoarthritis
13.18.4. Lupus
13.18.5. Gout
13.18.6. Others
13.19. Japan Rheumatology Therapeutics Market Forecast, By Drug Type
13.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
13.19.2. Analgesics
13.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.19.4. Corticosteroids
13.19.5. Uric Acid
13.19.6. Others
13.20. Japan Rheumatology Therapeutics Market Forecast, by Distribution Channel
13.20.1. Retail Pharmacy
13.20.2. Online Pharmacy
13.20.3. Hospitals
13.20.4. Others
13.21. ASEAN Rheumatology Therapeutics Market Forecast, By Disease Type
13.21.1. Rheumatoid Arthritis
13.21.2. Ankylosing Spondylitis
13.21.3. Osteoarthritis
13.21.4. Lupus
13.21.5. Gout
13.21.6. Others
13.22. ASEAN Rheumatology Therapeutics Market Forecast, By Drug Type
13.22.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
13.22.2. Analgesics
13.22.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.22.4. Corticosteroids
13.22.5. Uric Acid
13.22.6. Others
13.23. ASEAN Rheumatology Therapeutics Market Forecast, by Distribution Channel
13.23.1. Retail Pharmacy
13.23.2. Online Pharmacy
13.23.3. Hospitals
13.23.4. Others
13.24. Rest of Asia Pacific Rheumatology Therapeutics Market Forecast, By Disease Type
13.24.1. Rheumatoid Arthritis
13.24.2. Ankylosing Spondylitis
13.24.3. Osteoarthritis
13.24.4. Lupus
13.24.5. Gout
13.24.6. Others
13.25. Rest of Asia Pacific Rheumatology Therapeutics Market Forecast, By Drug Type
13.25.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
13.25.2. Analgesics
13.25.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
13.25.4. Corticosteroids
13.25.5. Uric Acid
13.25.6. Others
13.26. Rest of Asia Pacific Rheumatology Therapeutics Market Forecast, by Distribution Channel
13.26.1. Retail Pharmacy
13.26.2. Online Pharmacy
13.26.3. Hospitals
13.26.4. Others
13.27. Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis
13.27.1. By Disease Type
13.27.2. By Drug Type
13.27.3. By Distribution Channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Development
14. Middle East & Africa Rheumatology Therapeutics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Rheumatology Therapeutics Market Overview
14.3. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, By Disease Type
14.4. Middle East & Africa Rheumatology Therapeutics Market Forecast, By Disease Type
14.4.1. Rheumatoid Arthritis
14.4.2. Ankylosing Spondylitis
14.4.3. Osteoarthritis
14.4.4. Lupus
14.4.5. Gout
14.4.6. Others
14.5. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, By Drug Type
14.6. Middle East & Africa Rheumatology Therapeutics Market Forecast, By Drug Type
14.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
14.6.2. Analgesics
14.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.6.4. Corticosteroids
14.6.5. Uric Acid
14.6.6. Others
14.7. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel
14.8. Middle East & Africa Rheumatology Therapeutics Market Forecast, by Distribution Channel
14.8.1. Retail Pharmacy
14.8.2. Online Pharmacy
14.8.3. Hospitals
14.8.4. Others
14.9. Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country
14.10. Middle East & Africa Rheumatology Therapeutics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Rheumatology Therapeutics Market Analysis, by Country
14.12. GCC Rheumatology Therapeutics Market Forecast, By Disease Type
14.12.1. Rheumatoid Arthritis
14.12.2. Ankylosing Spondylitis
14.12.3. Osteoarthritis
14.12.4. Lupus
14.12.5. Gout
14.12.6. Others
14.13. GCC Rheumatology Therapeutics Market Forecast, By Drug Type
14.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
14.13.2. Analgesics
14.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.13.4. Corticosteroids
14.13.5. Uric Acid
14.13.6. Others
14.14. GCC Rheumatology Therapeutics Market Forecast, by Distribution Channel
14.14.1. Retail Pharmacy
14.14.2. Online Pharmacy
14.14.3. Hospitals
14.14.4. Others
14.15. South Africa Rheumatology Therapeutics Market Forecast, By Disease Type
14.15.1. Rheumatoid Arthritis
14.15.2. Ankylosing Spondylitis
14.15.3. Osteoarthritis
14.15.4. Lupus
14.15.5. Gout
14.15.6. Others
14.16. South Africa Rheumatology Therapeutics Market Forecast, By Drug Type
14.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
14.16.2. Analgesics
14.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.16.4. Corticosteroids
14.16.5. Uric Acid
14.16.6. Others
14.17. South Africa Rheumatology Therapeutics Market Forecast, by Distribution Channel
14.17.1. Retail Pharmacy
14.17.2. Online Pharmacy
14.17.3. Hospitals
14.17.4. Others
14.18. Rest of Middle East & Africa Rheumatology Therapeutics Market Forecast, By Disease Type
14.18.1. Rheumatoid Arthritis
14.18.2. Ankylosing Spondylitis
14.18.3. Osteoarthritis
14.18.4. Lupus
14.18.5. Gout
14.18.6. Others
14.19. Rest of Middle East & Africa Rheumatology Therapeutics Market Forecast, By Drug Type
14.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
14.19.2. Analgesics
14.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
14.19.4. Corticosteroids
14.19.5. Uric Acid
14.19.6. Others
14.20. Rest of Middle East & Africa Rheumatology Therapeutics Market Forecast, by Distribution Channel
14.20.1. Retail Pharmacy
14.20.2. Online Pharmacy
14.20.3. Hospitals
14.20.4. Others
14.21. Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis
14.21.1. By Disease Type
14.21.2. By Drug Type
14.21.3. By Distribution Channel
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Development
15. South America Rheumatology Therapeutics Market Analysis
15.1. Key Findings
15.2. South America Rheumatology Therapeutics Market Overview
15.3. South America Rheumatology Therapeutics Market Value Share Analysis, By Disease Type
15.4. South America Rheumatology Therapeutics Market Forecast, By Disease Type
15.4.1. Rheumatoid Arthritis
15.4.2. Ankylosing Spondylitis
15.4.3. Osteoarthritis
15.4.4. Lupus
15.4.5. Gout
15.4.6. Others
15.5. South America Rheumatology Therapeutics Market Value Share Analysis, By Drug Type
15.6. South America Rheumatology Therapeutics Market Forecast, By Drug Type
15.6.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
15.6.2. Analgesics
15.6.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
15.6.4. Corticosteroids
15.6.5. Uric Acid
15.6.6. Others
15.7. South America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel
15.8. South America Rheumatology Therapeutics Market Forecast, by Distribution Channel
15.8.1. Retail Pharmacy
15.8.2. Online Pharmacy
15.8.3. Hospitals
15.8.4. Others
15.9. South America Rheumatology Therapeutics Market Value Share Analysis, by Country
15.10. South America Rheumatology Therapeutics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Rheumatology Therapeutics Market Analysis, by Country
15.12. Brazil Rheumatology Therapeutics Market Forecast, By Disease Type
15.12.1. Rheumatoid Arthritis
15.12.2. Ankylosing Spondylitis
15.12.3. Osteoarthritis
15.12.4. Lupus
15.12.5. Gout
15.12.6. Others
15.13. Brazil Rheumatology Therapeutics Market Forecast, By Drug Type
15.13.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
15.13.2. Analgesics
15.13.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
15.13.4. Corticosteroids
15.13.5. Uric Acid
15.13.6. Others
15.14. Brazil Rheumatology Therapeutics Market Forecast, by Distribution Channel
15.14.1. Retail Pharmacy
15.14.2. Online Pharmacy
15.14.3. Hospitals
15.14.4. Others
15.15. Mexico Rheumatology Therapeutics Market Forecast, By Disease Type
15.15.1. Rheumatoid Arthritis
15.15.2. Ankylosing Spondylitis
15.15.3. Osteoarthritis
15.15.4. Lupus
15.15.5. Gout
15.15.6. Others
15.16. Mexico Rheumatology Therapeutics Market Forecast, By Drug Type
15.16.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
15.16.2. Analgesics
15.16.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
15.16.4. Corticosteroids
15.16.5. Uric Acid
15.16.6. Others
15.17. Mexico Rheumatology Therapeutics Market Forecast, by Distribution Channel
15.17.1. Retail Pharmacy
15.17.2. Online Pharmacy
15.17.3. Hospitals
15.17.4. Others
15.18. Rest of South America Rheumatology Therapeutics Market Forecast, By Disease Type
15.18.1. Rheumatoid Arthritis
15.18.2. Ankylosing Spondylitis
15.18.3. Osteoarthritis
15.18.4. Lupus
15.18.5. Gout
15.18.6. Others
15.19. Rest of South America Rheumatology Therapeutics Market Forecast, By Drug Type
15.19.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
15.19.2. Analgesics
15.19.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs)
15.19.4. Corticosteroids
15.19.5. Uric Acid
15.19.6. Others
15.20. Rest of South America Rheumatology Therapeutics Market Forecast, by Distribution Channel
15.20.1. Retail Pharmacy
15.20.2. Online Pharmacy
15.20.3. Hospitals
15.20.4. Others
15.21. South America Rheumatology Therapeutics Market Attractiveness Analysis
15.21.1. By Disease Type
15.21.2. By Drug Type
15.21.3. By Distribution Channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Development
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Abbvie, Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Company Footprint
16.3.2. Bristol-Myers Squibb Company,
16.3.3. Pfizer, Inc.
16.3.4. Merck & Co., Inc.
16.3.5. Amgen, Inc.
16.3.6. Novartis AG
16.3.7. Janssen Biotech, Inc.
16.3.8. Sanofi
16.3.9. Genentech, Inc.
16.3.10. Takeda Pharmaceutical
16.3.11. Johnson & Johnson Private Limited
16.3.12. F. Hoffmann-La Roche Ltd
16.3.13. UCB S.A.
16.3.14. Gilead Sciences, Inc.
16.3.15. Boehringer Ingelheim International GmbH
16.3.16. Regeneron Pharmaceuticals Inc.
17. Primary Key Insights